Pfizer raised its full-year 2026 outlook after outperforming in the third quarter. It now expects revenue of $62.0 billion to $64.0 billion and adjusted diluted EPS of $2.95 to $3.05.
Pfizer Inc. raised its full-year outlook after outperforming in the third quarter. The company increased its full-year 2026 revenue guidance by $1.5 billion at the midpoint, to a range of $62.0 to $64.0 billion.
Pfizer also raised and narrowed its full-year 2026 adjusted diluted EPS guidance to a range of $2.95 to $3.05. The company now expects full-year revenue of $62 billion to $64 billion and adjusted earnings of $2.95 to $3.05 a share.
